Elisei, R <br/><br/>
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.  [electronic resource] 

 -  The Journal of clinical endocrinology and metabolism  Nov 2009 
 - 4171-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1945-7197 
<br/><br/><label>Standard No.: </label>10.1210/jc.2009-0869  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma, Follicular--drug therapy<br/>Adult<br/>Aged<br/>Carcinoma, Papillary--drug therapy<br/>Combined Modality Therapy<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Iodine Radioisotopes--therapeutic use<br/>Male<br/>Middle Aged<br/>Recombinant Proteins--therapeutic use<br/>Thyroglobulin--blood<br/>Thyroid Hormones--administration & dosage<br/>Thyroid Neoplasms--drug therapy<br/>Thyroidectomy<br/>Thyrotropin--therapeutic use<br/>Treatment Outcome